Lilly Launched Global IT Innovations Lab inChina, to Assist in Improving Patient Outcomes Lilly reinforces commitment to innovation and China through new IT facility in Dalian DALIAN, March 19, 2013 /PRNewswire/ -- Eli Lilly and Company( http://www.lilly.com ) (NYSE: LLY) opened its new Lilly Global IT Innovations Lab at a ceremony in Dalian, China on March 18. The lab supports Lilly's mission to improve patient outcomes by making medicines that help people live longer, healthier, more active lives, by providing innovative IT solutions targeted at diseases that are widespread in China and across the world.
Investing in China's future Established as an Innovation Partnership with InnoCellence Systems Pte Ltd, the Lilly Global IT Innovations Lab is a world-class facility equipped with the latest technology and security to provide robust support to Lilly's investment in China as well as to advance Lilly's enterprise-wide IT capabilities. The lab will leverage advanced technological capabilities, highly skilled staff and Lilly's global presence to discover and develop innovative IT solutions that will better serve our healthcare providers and patients. At the opening ceremony, Eric Baclet, President and General Manager of Lilly China said, "Innovation in IT directly supports our core businesses in R&D and customer services to healthcare professionals and patients. The lab will not only provide high quality, innovative pharmaceutical IT solutions and services to improve patient outcomes in China's most prevalent diseases, it is also a clear demonstration of Lilly's commitment to being in China, for China and our confidence in this market." China is one of Lilly's top priority markets worldwide. "We are helping China grow in many ways," said Jacques Tapiero, Lilly's Senior Vice President and President, Emerging Market Business Unit. "Lilly has cultivated a network of productive collaborations with scientists and companies in China, while extending its presence in China to invest across the full value chain. Over the past year, Lilly has made a series of major investments which underpin our commitment to this market. The Lilly Global IT Innovations Lab demonstrates our continued commitment to innovation and to China," he added. "Innovation is in our DNA"Jeffrey Balagna, Lilly's Senior Vice President and Chief Information Officer, said, "At Lilly, innovation is in our DNA, not only through the breakthrough medicines we discover and develop, but also through innovative IT solutions like those that will emerge from the lab we've opened today in support of our pipeline, products and the patients we serve." The Lilly Global IT Innovations Lab will provide a secure platform for Lilly to collaborate with innovative solution partners both in China and across the globe. With its virtual platform www.LillyInnovations.com, it creates a channel for both Lilly and innovative solution providers the opportunity to work virtually together in exciting new ways."The new lab in Dalian will not only demonstrate our commitment to innovation in China, but it will also be leveraged to drive advances for patients around the world," said Piers Shore, Lilly's Vice President and Information Officer, Emerging Markets, Japan.
Aligned with government priorities Healthcare and related support services are on track to benefit from the Chinese government's campaign to boost domestic innovation. Both have been identified in the 12th 5-Year Plan as a good source of innovation, creativity, higher-paying jobs, value-added products, and better services to support domestic consumption. This focus on innovation in healthcare will in turn impact on the government's overall effort to improve the quality of its socioeconomic growth. Mr. Yan Hui, Deputy Director-General of Information Center, State Food and Drug Administration of China commented that Lilly's new lab supports the government's efforts to develop China's innovation capabilities and improve people's quality of life, noting Lilly's proven record of commitment to the China market. "Since the late 1990s, Lilly has invested more than RMB 2 billion (nearly US $300 million) across its value chain in China, which has now been strengthened with the new Lilly Global IT Innovations Lab in Dalian. Lilly's substantial investments in China, which range from pharmaceutical research and development to manufacturing and community welfare programs, demonstrate an excellent example of how multinational firms can make a positive impact in China," said Hui.
Win-win innovation partnership InnoCellence is honored to be able partner with Lilly to create and support their Lilly Global IT Innovations Lab. InnoCellence's global teams are committed to achieving excellence while supporting and working with Lilly on IT innovations and projects that add value to the world's healthcare.
About InnoCellence InnoCellence is a Singapore-based company specializing in IT Innovation, Mobility and User Experience. With offices in Singapore, China, Japan and the UK, InnoCellence works with leading multi-national corporations and forges lasting partnerships with its clients, applying emerging digital innovations to strategic business priorities. The team's expertise is varied and many team members have undertaken senior strategic roles in the pharmaceutical industry. This gives the company specialist knowledge of how to apply digital innovation to develop the industry and improve life for health care professionals and patients. Additional information about InnoCellence is available at www.innocellence.com. SOURCE Lily China
礼来全球信息技术创新中心正式投入运营 发布时间：2013-3-19 来源：药品资讯网信息中心美国礼来制药18日宣布，礼来全球信息技术创新中心正式成立。该中心将专注于研发创新的医疗信息技术解决方案，为中国乃至全球的疾病患者提供创新的医疗信息技术服务支持，改善患者的疗效。礼来全球信息技术创新中心的成立是礼来制药对中国做出的又一重大且具有持续性的承诺，同时也再次呼应了礼来制药的使命：致力于为全人类提供以药物为基础的创新医疗保健方案，使人们生活得更长久、更健康、更有活力。
投资中国的未来 礼来全球信息技术创新中心是礼来制药与英诺瑞新系统有限公司(InnoCellence Systems Pte Ltd)进行创新合作的结晶。这一世界级的创新中心将采用最新的IT技术和应用，并研究这些最新的技术和应用如何更好地运用到礼来制药的公司业务中，在大幅提升礼来制药自身企业IT能力的同时，为礼来制药在中国进行的系列投资提供良好的信息技术支持。更重要的，该中心将凭借先进的技术能力、高素质的员工队伍和礼来制药的全球网络来开发创新的医疗信息技术解决方案。 礼来中国总裁艾博来（Eric Baclet）表示："我们相信礼来全球信息技术创新中心的成立可以为礼来研发，以及针对医疗专业人士和患者的客户服务方面提供大力支持。礼来全球信息技术创新中心不仅将提供优质、创新的医疗信息技术解决方案和服务，从而改善在中国最常见疾病领域的患者疗效；同时也再次印证了礼来'植根中国、造福中国'的决心和对中国市场的信心。" 中国是礼来制药在全球范围内最重要的市场之一。礼来制药高级副总裁、新兴市场总裁戴柏豪 (Jacques Tapiero) 表示："我们在各个方面帮助礼来中国不断成长。我们与中国的科学家和企业进行了广泛的富有成效的合作，同时也在扩大礼来在中国的布局，对研发、生产、物流等在内的整个价值链进行投资。在刚刚过去的一年，我们就对中国进行了一系列重大投资。礼来全球信息技术创新中心的成立进一步践行了我们对于中国市场的投资承诺以及对创新的不懈追求。" 凝聚全球智慧 作为一家拥有137年历史的以研发为基础的医药公司，以研发为主导的创新可以说是礼来制药持续发展的灵魂和核心。礼来制药高级副总裁兼首席信息官杰弗里(Jeffrey A. Balagna)表示："创新是植入礼来制药的基因。作为一家创新驱动型的企业，在礼来，只有那些显著改善了人们的生活的想法才能被视为创新。" 基于最新的IT技术和应用，礼来全球信息技术创新中心将为中国及全球的创新解决方案的合作伙伴提供一个虚拟平台：www.LillyInnovations.com。通过这个虚拟平台，礼来的IT专业人士和全球的信息技术创新解决方案提供商就有机会以全新的虚拟方式在一起合作。 "在中国大连设立的这一全球信息技术创新中心将极大地深化我们在中国的创新承诺。我们在全球的各个业务单位都可以有效地利用公司的这一网络平台开发创新的医疗信息技术解决方案，以应对中国和世界各地最紧迫的医疗和业务技术挑战"，礼来制药新兴市场及日本区副总裁、全球信息技术创新负责人皮尔思•肖尔（Piers Shore）说。
符合中国政府创新发展的主旋律 创新驱动已经成为中国政府当前及未来发展的主旋律，而医疗及相关支持服务将会受益于中国政府促进国内创新的举措。在中国政府的"十二五"规划中，医疗及相关支持服务被明确定义为"可支持国内消费的创新、创造力、高薪就业、高附加值产品和更优质服务的良好来源，推动国内消费"。与此同时，关注医疗保健创新也与中国政府努力改善整体社会经济发展质量的大方向一致。 国家食品药品监督管理局信息中心副主任燕辉在高度评价礼来制药对于中国市场的坚定承诺时指出，礼来制药新开设的这一全球信息技术创新中心支持了中国政府发展中国的创新能力及改善人民生活质量的努力。"自20世纪90年代末以来，礼来已向其在中国的价值链投入了20多亿人民币（近3亿美元），而在大连新开设的这一礼来全球信息技术创新中心进一步巩固了这些投资。礼来制药在中国进行的重大投资涵盖了从医药研发到生产制造及社区健康计划，很好地证明了跨国公司如何在中国产生积极的影响。" 双赢的创新合作 作为礼来全球信息技术创新中心的技术合作伙伴，英诺瑞新系统有限公司(InnoCellence Systems Pte Ltd)全球团队致力于实现卓越，同时将在为世界医疗领域创造价值的IT解决方案和项目上为礼来制药提供支持和合作。
No comments:
Post a Comment